Issuer and reporting period
Important issuer mismatch: The supplied filing is Nemus Bioscience, Inc.’s Form 10-K, not a filing for Skye Bioscience, Inc. It reports the fiscal year ended December 31, 2016, with 2015 comparisons; it is an annual report, not a standalone fourth-quarter report.
Nemus was an early-stage cannabinoid therapeutics company partnered with the University of Mississippi (UM). Its candidates were preclinical or in research, and it had no product revenue.
Financial results and liquidity
| Metric | FY 2016 | FY 2015 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $939,040 | $576,093 |
| General and administrative expense | $3,531,540 | $3,741,017 |
| Total operating expenses / operating loss | $4,470,580 | $4,317,110 |
| Net loss | $3,178,093 | $4,841,161 |
| Net loss per common share | $0.17 | $0.29 |
| Cash used in operations | $3,552,941 | $3,727,989 |
Net loss narrowed mainly because of noncash fair-value income on Series B warrants; operating loss increased as R&D spending rose. The filing reports no gross margin because there was no revenue.
At December 31, 2016, cash and cash equivalents were $64,820, down from $3,221,209 a year earlier; restricted cash was $37,500. Current assets were $279,489 against current liabilities of $661,958, a working-capital deficit of approximately $382,000. Total assets were $323,363 and total liabilities were $1,774,266. The balance sheet also included redeemable convertible preferred stock and a $1,112,308 Series B warrant liability. No conventional borrowings are shown in the provided balance sheet.
Financing activities provided $407,669 in 2016, compared with $6,743,850 in 2015. After year-end, Nemus raised $1.2 million gross from Series D preferred stock in January 2017. Management said cash on hand was expected to fund operations for at least four months, but without further funding it did not expect to meet obligations beyond one year after issuance of the financial statements. The auditor and management identified substantial doubt about the company’s ability to continue as a going concern.
Changes, outlook, and material risks
- R&D expense increased about 63% year over year, primarily for formulation work, license renewals, options, and UM research. G&A decreased about 6%.
- Net loss improved by about $1.66 million, substantially reflecting a $1.34 million noncash gain from the change in fair value of Series B warrant liabilities. This is not operating revenue or cash generation.
- Pipeline candidates included NB1111 for glaucoma, NB1222 for chemotherapy-induced nausea and vomiting, and NB3111 for MRSA, all described as preclinical; NB2111 and NB2222 remained in research. The filing gives no firm clinical-trial start date. Management planned to seek FDA guidance for NB1222 and described potential Phase 2a glaucoma testing for NB1111 subject to an effective IND.
- In January 2017, Nemus licensed UM 5070 for infectious-disease development. The company relied heavily on UM and external manufacturers and research providers; the filing highlights regulatory uncertainty around cannabis cultivation, handling, controlled-substance registrations, and eventual product scheduling.
- Series B and C conversion prices and Series B warrant exercise prices were reset to $0.25 following the Series D financing. The preferred stock, warrants, options, and financing terms create significant potential dilution and contingent redemption/liquidity risks.
- Other key risks include the need for substantial additional capital, no approved products or revenues, clinical and regulatory failure, dependence on UM and third parties, thin OTCQB trading, and uncertainty over coverage and reimbursement. Management reported effective disclosure controls and internal control over financial reporting at year-end.
Key facts investors should verify
- Confirm the intended issuer: this document identifies Nemus Bioscience, Inc., not Skye Bioscience, Inc.
- Review the full audited statements and subsequent financing documents, including the terms and net proceeds of the January 2017 Series D issuance and the company’s post-financing cash runway.
- Check the preferred-stock conversion, anti-dilution, warrant, and redemption provisions and quantify potential dilution against the outstanding common shares.
- Verify current development status, FDA/DEA requirements, and UM license and research arrangements; the filing’s development plans are forward-looking, not achieved milestones.
- Assess the going-concern warning and distinguish recurring operating costs and cash burn from noncash fair-value gains that reduced reported net loss.